Forte Bio surges on early-stage trial data for vitiligo therapy
Seeking Alpha ·
Shares of Forte Biosciences ( FBRX ) climbed on Thursday after the company posted early-stage trial results indicating that its lead asset, FB102, led to a statistically significant improvement in vitiligo symptoms as early as nine weeks.
DYAX Investor Sentiment
Bullish (Long) 55% · Bearish (Short) 45%
245 participants
Related News
- Fads may fade, but Five Below keeps shoppers engaged — Mizuho
- Nvidia likely only to sell a small number of GPUs to China, Wells Fargo says
- Starbucks Targets $400 Million Software Spend With AI Shift
- New York Times, others urge court to sanction OpenAI in copyright tussle
- Fervo Energy surges as faster Cape Station drilling seen lowering cost concerns
- Applied Materials CEO says AI investment splurge might extend longer than expected